

TABLE 1—DRUG PRODUCTS NOT WITHDRAWN FROM SALE FOR REASONS OF SAFETY OR EFFECTIVENESS—Continued

Application No.	Drug name	Active ingredient(s)	Strength(s)	Dosage form/route	Applicant
NDA 021227 .....	CANCIDAS .....	Caspofungin Acetate .....	50 mg/Vial; 70 mg/Vial .....	Powder; Intravenous .....	Merck Sharp & Dohme.
NDA 021506 .....	MYCAMINE .....	Micafungin Sodium .....	EQ 50 mg Base/Vial; EQ 100 mg Base/Vial.	Injectable; Intravenous ..	Astellas Pharma US Inc.
NDA 021520 .....	SYMBYAX .....	Fluoxetine Hydrochloride; Olanzapine.	EQ 25 mg Base; EQ 3 mg Base; EQ 25 mg Base; EQ 6 mg Base; EQ 25 mg Base; EQ 12 mg Base; EQ 50 mg Base; EQ 6 mg Base; EQ 50 mg Base; EQ 12 mg Base.	Capsule; Oral .....	Eli Lilly and Co.
NDA 021947 .....	FENTORA .....	Fentanyl Citrate .....	EQ 0.1 mg Base; EQ 0.2 mg Base; EQ 0.4 mg Base; EQ 0.6 mg Base; EQ 0.8 mg Base.	Tablet; Buccal, Sublingual.	Cephalon, LLC.
NDA 022076 .....	LOCOID .....	Hydrocortisone Butyrate	0.1% .....	Lotion; Topical .....	Bausch Health.
NDA 022116 .....	LEXIVA .....	Fosamprenavir Calcium	EQ 50 mg Base/mL .....	Suspension; Oral .....	ViiV Healthcare.
NDA 022224 .....	TRILIPIX .....	Choline Fenofibrate .....	EQ 45 mg Fenofibric Acid; EQ 135 mg Fenofibric Acid.	Capsule, Delayed Release; Oral.	AbbVie Inc.
NDA 022525 .....	NAMENDA XR .....	Memantine Hydrochloride.	14 mg; 21 mg; 28 mg .....	Capsule, Extended Release; Oral.	AbbVie Inc.
NDA 022573 .....	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.	Ethinyl Estradiol; Norethindrone.	0.025 mg; 0.8 mg .....	Tablet, Chewable; Oral	Teva Branded Pharmaceutical Products R&D, Inc.
NDA 050007 .....	VIBRAMYCIN .....	Doxycycline Hyclate .....	EQ 100 mg Base .....	Capsule; Oral .....	Pfizer, Inc.
NDA 050537 .....	CLEOCIN .....	Clindamycin Phosphate	EQ 1% Base .....	Swab; Topical .....	Pfizer, Inc.
ANDA 080615 .....	DIMENHYDRINATE .....	Dimenhydrinate .....	50 mg/mL .....	Injectable; Injection.	
ANDA 084499 .....	ESTRACE .....	Estradiol .....	1 mg .....	Tablet; Oral .....	Bristol Myers Squibb.
ANDA 084500 .....	ESTRACE .....	Estradiol .....	2 mg .....	Tablet; Oral .....	Bristol Myers Squibb.
ANDA 088023 .....	ADIPEX-P .....	Phentermine Hydrochloride.	37.5 mg .....	Capsule; Oral .....	Teva USA.
NDA 204300 .....	VAZCULEP .....	Phenylephrine Hydrochloride.	10 mg/mL (10 mg/mL); 50 mg/5 mL; 100 mg/10 mL.	Solution; Intravenous .....	Exela Pharma Sciences.
NDA 204412 .....	DELZICOL .....	Mesalamine .....	400 mg .....	Capsule, Delayed Release; Oral.	AbbVie Inc.
NDA 208418 .....	CALCIUM GLUCONATE	Calcium Gluconate .....	1 g/50 mL; 2 g/100mL .....	Solution; Intravenous .....	Fresenius Kabi USA, LLC.
NDA 209091 .....	QTERN .....	Dapagliflozin; Saxagliptin Hydrochloride.	5 mg; EQ 5 mg Base 10 mg; EQ 5 mg Base.	Tablet; Oral .....	AstraZeneca AB.

FDA has reviewed its records and, under § 314.161, has determined that the drug products listed were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list the drug products in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.

Approved ANDAs that refer to the drug products listed are unaffected by the discontinued marketing of the products subject to these applications. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

**Grace R. Graham,**

*Deputy Commissioner for Policy, Legislation, and International Affairs.*

[FR Doc. 2026–11429 Filed 6–5–26; 8:45 am]

**BILLING CODE 4164–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Career Development Training.

*Date:* July 7, 2026.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Tushar Baran Deb, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Rockville, MD 20850, (240) 276–6132, [tushar.deb@nih.gov](mailto:tushar.deb@nih.gov).

*Name of Committee:* Infectious Diseases and Immunology A Integrated Review Group; Bacterial Virulence Study Section.

*Date:* July 7–8, 2026.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Susan Daum, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, Bethesda, MD 20892, 301–827–7233, [susan.boyle-vavra@nih.gov](mailto:susan.boyle-vavra@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; NIDCD Clinical Research Center Grant (P50) Review.

*Date:* July 7, 2026.

*Time:* 10:00 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.  
*Contact Person:* Li Jia, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451-2854, [li.jia@nih.gov](mailto:li.jia@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Training and Career Development: Clinical Care, Treatment & Disease Management.

*Date:* July 8–9, 2026.

*Time:* 9:00 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Trina Colleen Salm Ward, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-5254, [salmwardtc@csr.nih.gov](mailto:salmwardtc@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Fellowships: Clinical Neurosciences.

*Date:* July 8–9, 2026.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Anita T Tandle, Ph.D., Scientific Review Officer, Center or Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 204-0329, [tandlea@mail.nih.gov](mailto:tandlea@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR-24-268: Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program.

*Date:* July 8, 2026.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Dylan P Flather, Ph.D., Scientific Review Officer, Center or Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (406) 802-6209, [dylan.flather@nih.gov](mailto:dylan.flather@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Cancer Etiology, Diagnosis, Prevention and Treatment.

*Date:* July 8, 2026.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Hasan Siddiqui, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451-0395, [hasan.siddiqui@nih.gov](mailto:hasan.siddiqui@nih.gov).

*Name of Committee:* Center for Scientific Review, Special Emphasis Panel; Biological Processes and Social-Ecological Factors.

*Date:* July 8–9, 2026.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Brittany L Mason-Mah, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000A, Bethesda, MD 20892, (301) 594-3163, [masonmahbl@mail.nih.gov](mailto:masonmahbl@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Special: Cardiovascular and Circulation.

*Date:* July 8, 2026.

*Time:* 10:00 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Nakia C Brown, Ph.D., Scientific Review Officer, Center or Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-827-4905, [brownnac@mail.nih.gov](mailto:brownnac@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics in Adaptive and Innate Immunity.

*Date:* July 8, 2026.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Diana Maria Ortiz-Garcia, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-5614, [diana.ortiz-garcia@nih.gov](mailto:diana.ortiz-garcia@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 3, 2026.

**Denise M. Santeufemio,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-11390 Filed 6-5-26; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Child Health and Human Development Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: <http://videocast.nih.gov/>.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Child Health and Human Development Council.

*Date:* October 14, 2026.

*Open:* 9:00 a.m. to 1:45 p.m.

*Agenda:* Introductory Remarks; NICHD Director's Report; Concept Clearance; Invited Director: Clinical Center; Annual Division of Intramural Research; Scientific Presentation; Voice of the Participant; Remarks from Retiring Members.

*Address:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Meeting Format:* In Person.

*Closed:* 2:00 p.m. to 5:00 p.m.

*Agenda:* Review of Applications, Closing Remarks; Adjournment.

*Address:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Meeting Format:* In Person.

*Contact Person:* Rebekah S. Rasooly, Ph.D., Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20817, Phone: 301-827-2599, Email: [Rebekah.rasooly@nih.gov](mailto:Rebekah.rasooly@nih.gov).

Registration is not required to attend the open portion of this meeting.